Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Recent acquisitions in hyaline membrane disease].

G Bona, G C Mussa

    Minerva Medica
    |August 4, 1977
    PubMed
    Summary

    Hyaline membrane disease in premature infants stems from delayed lung maturation and surfactant deficiency. Prophylaxis with preformed surfactant factors offers the most significant improvement in prognosis for this serious condition.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A low-dose multicomponent medication as a new approach in prevention and early add-on treatment of recurrent respiratory infections in children: a Delphi Consensus.

    European review for medical and pharmacological sciences·2024
    Same author

    Safety and effectiveness of a somatropin biosimilar in children requiring growth hormone treatment: second analysis of the PATRO Children study Italian cohort.

    Journal of endocrinological investigation·2020
    Same author

    Evaluation of growth hormone response to GHRH plus arginine test in children with idiopathic short stature: role of peak time.

    Journal of endocrinological investigation·2018
    Same author

    Can Type 1 diabetes progression be halted? Possible role of high dose vitamin D and omega 3 fatty acids.

    European review for medical and pharmacological sciences·2017
    Same author

    A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

    Cell death and differentiation·2016
    Same author

    A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

    Cell death and differentiation·2016

    Area of Science:

    • Neonatal Medicine
    • Pulmonary Biology
    • Biochemistry